AveXis Inc. (AVXS)

217.83
0.18 0.08
Prev Close 217.65
Open 217.78
Day Low/High 217.71 / 217.94
52 Wk Low/High 65.54 / 217.94
Volume 884.12K
Avg Volume 858.10K
Exchange
Shares Outstanding 36.82M
Market Cap 8.02B
EPS -7.30
Div & Yield N.A. (N.A)

Latest News

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss the FAANG stocks, a market bottom, and potential biotech targets.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

We Got Too Negative: Cramer's 'Mad Money' Recap (Monday 4/9/18)

Jim Cramer says we're seeing powerful reminders that there's a better time to sell than in the teeth of a decline. Investors must use discipline to their advantage.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.

5 Thing You Must Know Before Monday's Opening Bell

5 Thing You Must Know Before Monday's Opening Bell

U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

AveXis Enters Into Licensing Agreement With Genethon

AveXis Enters Into Licensing Agreement With Genethon

Includes exclusive worldwide rights to AAV9-SMN product and route of administration

AveXis To Report Fourth Quarter And Full Year 2017 Financial And Operating Results

AveXis To Report Fourth Quarter And Full Year 2017 Financial And Operating Results

Conference call and webcast on February 27 at 4:30 p.m. EST

First Week of AVXS August 17th Options Trading

First Week of AVXS August 17th Options Trading

Investors in AveXis Inc saw new options begin trading this week, for the August 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 221 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.